Antibodies are immunoglobulins (Ig) which are naturally produced by the immune system, whenever an antigen (foreign particles) invades in our body. These antigens include various types of microorganisms or viruses. Antibodies play a very crucial role in the body’s defense mechanism. The immune system of an animal can produce large group of antibodies which recognizes specific epitopes of an antigen.
Monoclonal antibodies are the antibodies which are produced in a laboratory from a clone of single B-cell. They recognize and bind to specific receptors present on the surface of cells. These antibodies are identical in nature, technically termed as identical immunoglobulin and are used to detect several disease agents and for diagnostic applications as well as for the treatment of cancer.
The monoclonal antibodies are produced with the generation of monoclonal antibodies producing cells which are called hybridomas. Mice are injected and immunized with an antigen and the generation of antibody production is screened. Antibody generation splenocytes which are the B-cells are isolated for the in vitro hybridoma production. Spleen cells are fused with the myeloma cells to form hybridomas in the presence of polyethylene glycol (PEG), which is responsible for the fusion of membranes. According to the antigen specificity and the class of immunoglobulin, clones are screened and selected. Potential high producing colonies are confirmed, validated and characterized. Scale up and expansion of antibody producing clones are done in large bioreactors or large flasks.
The market is observing a vibrant growth on account of increasing prevalence of chronic diseases as well as increase in the demand for biologics. Further, the advances in technology in the field of genetics platforms which includes next generation sequencing (NGS) along with cost effectiveness of technology which are needed for research purposes to produce monoclonal antibodies are anticipated to contribute to the growth of the market.
The monoclonal antibodies market is anticipated to record a CAGR of around 15.5% over the forecast period i.e. 2018-2027. The market is segmented by applications into autoimmune diseases, inflammatory diseases, infectious diseases, microbial diseases, cancer and others, out of which, the autoimmune disease segment is anticipated to dominate the global monoclonal antibodies market followed by cancer segment which is also expected to contribute significantly in the growth of the market as monoclonal antibodies are widely used for the treatment of cancer. CLICK TO DOWNLOAD SAMPLE REPORT
As per the report of World Health Organization, the global cancer burden has increased to 18.1 million new cases and the number of deaths due to cancer was 9.6 million in 2018. The worldwide increase in the cancer cases is one of the most important market drivers behind the growth of global monoclonal antibodies market as the monoclonal antibodies are extensively used for the treatment of cancer. They find and recognize several proteins on cancerous cells.
There is an increase in the demand for personalized medicine as enhancement in the research and development of therapeutic antibodies has paved way for targeted therapies because different people respond and behave differently to a particular treatment. Both monoclonal antibodies and chemotherapy are used for the treatment of cancer. Chemotherapy uses many harsh chemicals which destroy non-cancerous cells in the body and have side effects such as extreme weakness followed by rapid hair loss whereas monoclonal antibody mediated cancer therapy consists of proteins which specifically targets molecules present on the surface of the cell. As monoclonal antibody mediated cancer therapy use proteins, these therapies have comparatively lesser side effects than the conventional chemotherapy. Personalized treatment and lesser side effects of monoclonal antibody mediated cancer therapy is expected to augment the growth of the market.
One of the most important factor which is restraining the market growth is the high price associated with monoclonal antibodies as they are expensive both at the developmental stage and at the end use stage. Further, the escalating cost of research and development processes and growing price of treatments which are using monoclonal antibodies are estimated to restrain the growth of the market.
Our-in depth analysis of the global monoclonal antibodies market includes the following segments:
On the basis of regional analysis, the global monoclonal antibodies market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.
North America is expected to dominate the global monoclonal antibodies market as there are many established healthcare infrastructures around the region. Additionally, government is also putting more emphasis on infection and disease control. In the upcoming years, funding by the government will increase on research and development activities of cancer. These factors are anticipated to augment the growth of the market in this region.
Europe is expected to show a significant growth in the market due to increase in the prevalence of autoimmune diseases, rise in cancer population and increased funding in research and development activities in the field of monoclonal antibody therapeutics across the region. Further, the market in Asia-Pacific is expected grow significantly which can be attributed to the increase in spending capacity of people along with growing awareness among the patients.
The global monoclonal antibodies market is further classified on the basis of region as follows:
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization